Incyte reported fourth quarter 2025 earnings on Tuesday. The company's adjusted earnings per share of $1.80 missed analyst expectations of $1.94, though revenue of $1.51 billion exceeded Street forecasts. For the full year 2025, Incyte reported profit of $1.29 billion on revenue of $5.14 billion. The company issued 2026 revenue guidance below Wall Street estimates. Incyte's key growth driver Opzelura is expected to underperform forecasts. The company faces patent expiration of its top-selling drug Jakafi in 2028. Incyte plans to offset potential losses by expanding Opzelura and advancing its oncology and dermatology pipeline. Incyte shares fell 8.24 percent on Tuesday, closing at $100.05, ending a four-day winning streak. Morgan Stanley raised its price target on Incyte to $102 from $94 while maintaining an Equalweight rating.
Read full analysisIncyte reported fourth quarter 2025 earnings on Tuesday. The company's adjusted earnings per share of $1.80 missed analyst expectations of $1.94, though revenue of $1.51 billion exceeded Street forecasts. For the full year 2025, Incyte reported profit of $1.29 billion on revenue of $5.14 billion. The company issued 2026 revenue guidance below Wall Street estimates. Incyte's key growth driver Opzelura is expected to underperform forecasts. The company faces patent expiration of its top-selling drug Jakafi in 2028. Incyte plans to offset potential losses by expanding Opzelura and advancing its oncology and dermatology pipeline. Incyte shares fell 8.24 percent on Tuesday, closing at $100.05, ending a four-day winning streak. Morgan Stanley raised its price target on Incyte to $102 from $94 while maintaining an Equalweight rating.
Incyte Corporation (INCY) is a publicly traded company in the Healthcare sector.